Home/Filings/3/0000899243-20-022867
3//SEC Filing

Valor IV Pharma Holdings, LLC 3

Accession 0000899243-20-022867

CIK 0001802665other

Filed

Aug 17, 8:00 PM ET

Accepted

Aug 18, 9:48 PM ET

Size

24.4 KB

Accession

0000899243-20-022867

Insider Transaction Report

Form 3
Period: 2020-08-18
Holdings
  • Common Stock

    845,336
  • Series A Preferred Stock

    Common Stock (9,129,640 underlying)
  • Series C Preferred Stock

    Common Stock (217,527 underlying)
Holdings
  • Series A Preferred Stock

    Common Stock (9,129,640 underlying)
  • Series C Preferred Stock

    Common Stock (217,527 underlying)
  • Common Stock

    845,336
Holdings
  • Common Stock

    845,336
  • Series A Preferred Stock

    Common Stock (9,129,640 underlying)
  • Series C Preferred Stock

    Common Stock (217,527 underlying)
Footnotes (3)
  • [F1]Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein.
  • [F2]The Series A Preferred Stock is convertible into Common Stock on a 8.215-for-1 basis into the number of shares of Common Stock as shown in Column 3 at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. These shares have no expiration date.
  • [F3]The Series C Preferred Stock is convertible into Common Stock on a 8.215-for-1 basis into the number of shares of Common Stock as shown in Column 3 at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. These shares have no expiration date.

Issuer

Harmony Biosciences Holdings, Inc.

CIK 0001802665

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001821186

Filing Metadata

Form type
3
Filed
Aug 17, 8:00 PM ET
Accepted
Aug 18, 9:48 PM ET
Size
24.4 KB